

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jennifer Hayes on March 25, 2009.

The application has been amended as follows:

In claim 1, line 6, "(" has been deleted.

In claim 1, line 8, "molecule" has been substituted by --monomer--.

In claim 1, line 8, ")" has been deleted.

In claim 1, line 14, "molecule" has been substituted by --monomer--.

In claim 1, line 15, "(" has been substituted by --,--.

In claim 1, line 15, ")" has been deleted.

In claim 2, line 3, "molecule" has been substituted by --monomer--.

In claim 6, line 3, "(" has been substituted by --,--.

In claim 6, line 4, ")" has been deleted.

In claim 7, line 5, "(" has been substituted by --,--.

In claim 7, line 5, ")" has been deleted.

In claim 8, line 6, "(" has been deleted.

In claim 8, line 6, "or unsaturated" has been deleted.

Art Unit: 1796

In claim 8, line 8, "molecule)" has been substituted by --monomer, and--. [Support for this amendment can be found in the instant specification pg 6, line 10 – pg 7, line 3]

In claim 8, line 9, "as an essential ingredient," has been deleted.

In claim 8, line 15, "molecule" has been substituted by --monomer--.

In claim 8, line 19, "(" has been substituted by --,--.

In claim 8, line 20, ")" has been deleted.

In claim 9, line 3, "molecule" has been substituted by --monomer--.

In claim 13, line 3, "(" has been substituted by --,--.

In claim 13, line 4, ")" has been deleted.

In claim 14, line 5, "(" has been substituted by --,--.

In claim 14, line 6, ")" has been deleted.

In claim 17, line 2, "a monomer, which is" has been deleted.

In claim 17, line 5, "(" has been deleted.

In claim 17, line 5, "or unsaturated" has been deleted.

In claim 17, line 7, "molecule)" has been substituted by --monomer, and--.

[Support for this amendment can be found in the instant specification pg 7, line 18 – pg 8, line 7]

In claim 18, line 5, "(" has been deleted.

In claim 18, line 11, "r:" has been deleted.

In claim 18, line 11, ")" has been deleted.

Art Unit: 1796

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

### ***Correspondence***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jessica Paul whose telephone number is (571)270-5453. The examiner can normally be reached on Monday thru Friday 8:00- 6:00p; alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Eashoo can be reached on 571-272-1197. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1796

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/James J. Seidleck/  
Supervisory Patent Examiner, Art Unit 1796

Jessica Paul  
Examiner  
Art Unit 1796

/JMP/